The study investigates whether treatment with elacestrant (an oral selective estrogen receptor degrader: SERD) leads to better treatment outcomes compared to standard antihormonal therapy.
During the ctDNA screening phase, patient blood samples are regularly tested for circulating tumor DNA (ctDNA, so-called liquid biopsy). If ctDNA is detected, patients without evidence of distant metastases receive antihormonal therapy.
This is a randomized study. Patients receive either
elacestrant (oral) or
standard antihormonal therapy
The study investigates whether treatment with elacestrant (an oral selective estrogen receptor degrader: SERD) leads to better treatment outcomes compared to standard antihormonal therapy.
During the ctDNA screening phase, patient blood samples are regularly tested for circulating tumor DNA (ctDNA, so-called liquid biopsy). If ctDNA is detected, patients without evidence of distant metastases receive antihormonal therapy.
This is a randomized study. Patients receive either
elacestrant (oral) or
standard antihormonal therapy
